Paclitaxel-based drugs are commonly used adjuvant chemotherapy for gynecological cancer patients. Peripheral neuropathy, a side effect of this treatment, presents with symptoms such as numbness, tingling, decreased skin and reflex sensation, and impaired function in the hands and feet, thus affecting quality of life. Peripheral neuropathy is a side effect caused by the neurotoxicity of certain chemotherapeutic drugs, including paclitaxel and platinum-based drugs, resulting from the cumulative toxicity of specific drug doses. While numerous international studies have confirmed the preventative effects of hand and foot movement interventions, there is a lack of relevant literature in China. Therefore, this study aims to explore the effects of hand and foot movement interventions on elderly gynecological cancer patients undergoing chemotherapy.

Peripheral neuropathy is a fairly common clinical problem. Paclitaxel-based drugs are commonly used adjuvant chemotherapy for gynecological cancer patients, and peripheral neuropathy symptoms, including numbness, tingling, decreased skin and reflex sensation, and impaired function, can significantly impact quality of life. Peripheral neuropathy is a side effect caused by the neurotoxicity of certain chemotherapeutic drugs, including paclitaxel (Paclitaxel, Docetaxel) and platinum-based drugs (Cisplatin, Carboplatin). It results from the cumulative toxicity of specific drug doses. A study by Eroglu & Kutluturkan (2024) showed that in colorectal cancer patients receiving at least two cycles of platinum-based drugs, a hand and foot exercise program performed three times daily, three days a week, for eight weeks effectively reduced sensory and motor symptoms of peripheral neuropathy, as well as the severity, frequency, and emotional distress caused by symptoms, and the impact of symptoms on hand and foot dexterity. Another study reported that breast cancer patients receiving paclitaxel chemotherapy and diagnosed with grade I or higher neuropathy benefited from massage or stress ball exercises for eight weeks. These exercises helped reduce the incidence and severity of peripheral neuropathy during and after chemotherapy, prevented muscle weakness caused by peripheral neuropathy, and improved independent function and quality of life (Uysal & Toprak, 2025). Currently, there is a lack of empirical research in China on using hand-foot exercise interventions to improve peripheral neuropathy and quality of life in gynecological cancer patients undergoing chemotherapy, and care guidelines are severely lacking. More research is needed to confirm its efficacy. Therefore, this study aims to explore the effectiveness of hand-foot exercise interventions in improving peripheral neuropathy and quality of life in elderly gynecological cancer patients undergoing chemotherapy. Currently, many studies abroad have confirmed that hand and foot exercise intervention can effectively prevent [the condition]. We would like to invite you to participate in a research trial. You are free to decide whether or not to participate in this trial. Before receiving the hand and foot exercise at our hospital's obstetrics and gynecology outpatient clinic, we will explain the process and obtain your consent. We will provide you with a paper picture booklet of hand and foot exercises. After the researcher demonstrates the hand and foot exercise instructions to the participant using a massage ball, the researcher and the participant will perform the hand and foot exercises together one-on-one to confirm that the participant's movements are performed correctly. You can also watch the hand and foot exercise instructional video online. At the same time, you will be given a weekly exercise record sheet, indicating whether you have completed the exercise by checking a box. Participants will then perform the hand and foot exercises at home for 10-15 minutes each time, three times a day, three days a week, for twelve weeks. After that, you will return the exercise record sheet.

Inclusion Criteria:

Individuals aged 65 or older diagnosed with gynecological cancer (stage II to IV) by a physician, without skin or nail lesions.

Individuals who have received at least one course of chemotherapy within the past year and have peripheral neuropathy, with chemotherapy drugs including paclitaxel (Paclitaxel or Docetaxel) or platinum-based drugs (Cisplatin or Carboplatin), and may receive combined targeted or immunotherapy.

Individuals who are conscious and able to communicate in Mandarin, Taiwanese, or written language.

Exclusion Criteria:

Skin or nail lesions. Edema of 3+ or more in the extremities. History of diagnosis of diabetes, neuropathy, peripheral arterial ischemia, or multiple organ failure.

Distal bone or skin metastases. Patients who have interrupted chemotherapy. Patients who have participated in similar studies.